Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. - Wikidata - awgldk - TriplyDB

Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.

Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.

http://www.wikidata.org/entity/Q33560520

about

Pathogenesis and mechanisms of antibody-mediated hemolysis RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME)ABO incompatible renal transplants: Good or bad?Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes.Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin.Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.American Society of Nephrology Quiz and Questionnaire 2013: transplantation.Fetal intraperitoneal injection of immunoglobulin diminishes alloimmune hemolysis.On the dark side of therapies with immunoglobulin concentrates: the adverse events Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases.ABO-incompatible living donor kidney transplantation without post-transplant therapeutic plasma exchange.Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature.A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options.An update on ABO-incompatible kidney transplantation.Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg.Intravenous immunoglobulin in the treatment of neurologic disorders.Advances in pharmacotherapy to treat kidney transplant rejection.Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.The role of inflammation in intravenous immune globulin-mediated hemolysis.Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.Immunoglobulin-induced hemolysis, splenomegaly and inflammation in patients with antibody deficiencies.In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.The role of isoagglutinins in intravenous immunoglobulin-related hemolysis.Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database.Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin.Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management.Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.Occurrence of hemolytic reactions on the same day as immune globulin product administrations during 2008 to 2014.Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products.Anti-Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation.Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters.Severe intravenous immunoglobulin-induced hemolysis with pigment nephropathy managed with red cell exchange.Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.Laboratory Markers in Incomplete Kawasaki Disease according to Coronary Artery Outcome.

P2860

Q26801809-7D2E7D1B-A390-4E65-89BD-9E2D9B562B07 Q26824798-29022FFB-E9F0-4FA6-9D31-73E05EA1AA53 Q28236829-E7A79F20-E219-4678-B7B3-C43D863A4504 Q33408909-34429155-6236-45CB-9E27-593AC8DF4684 Q33424419-102E85A9-14E4-4D7E-9FC5-EDC95222A6F4 Q33435272-D0E5F9F6-6E4C-48BC-A8D4-90CFF6BE1B73 Q33835780-B277C213-C602-41F4-B1C6-59777CBEAE3C Q34757115-62BF59A3-AB9D-42E8-A12C-E538335D2452 Q35053458-0CAB086C-3B7D-4C6E-BF0B-A3FEFB39DBF4 Q35963373-B6BD850E-91CD-49B0-8313-8937379B7A0C Q36031039-C57FB9AF-16D1-4C99-BCF4-77174E90BD99 Q37318222-7CF23BD7-B3A0-47EA-ACAB-936CBA3C5F16 Q38155915-772BDB01-771E-4D6B-902C-AE95FD30A88A Q38188031-A445E798-9E0E-4C48-970C-B2096AEFD5FB Q38206175-A1792E3E-F4E2-4AF1-93C0-17D71830D4DD Q38267202-C519B430-0276-4C5C-97FC-0907A3308F7D Q38292793-2A03D782-162E-4B15-9AAC-A1562D38A557 Q38495457-D0B591E6-3BB3-4D83-BE31-8B6456E5AC90 Q38544529-1CF18A10-7EA5-439C-9B14-C1A717D2AAF7 Q38547186-453C7CE4-F14B-43F7-9F81-FB40191DF705 Q38547189-E4693EA8-9528-4AF1-A7AF-B7FE90B63320 Q38608516-CEC79463-3138-45AD-8FA7-477A394E288B Q38725835-ED3EB07B-7F31-422E-8CCB-D685D8E38CD4 Q39273058-B82F6D68-D43B-40F9-82B7-C7E0BC621948 Q40736591-3EEBA6AF-CFFA-4DDF-BAEA-AA51C69059B8 Q40736607-20241E82-92A1-4B30-A575-51D5343A03C8 Q41082808-D2C5E7A9-2AC8-4E13-BA9E-EFEAACB2EB97 Q41108151-A7B3BEF2-18AB-45AA-97F5-0ED0FD0797A8 Q41118002-9A98D5A4-9CFA-4FB7-8498-C234F2032B1F Q41881022-0FF6002D-4549-4BB6-9DEF-682E391B707A Q45072412-FE03C551-5878-4A3E-8FC9-B834523BB9E1 Q46382819-1B67E188-7508-45E4-82A6-81B7901FEF7D Q48230185-A21FB485-292D-4E2E-B4FE-392CFD75BA70 Q50113680-F0D2D709-33AA-4254-911C-F203253D00C6 Q50438105-68E24D74-B29F-4269-BE1C-9B9E491EF5B4 Q50954810-B4E17ABC-EE29-4EC9-ABEE-409A11B635C8 Q51649208-35D8C19B-E4E7-4579-8980-ED107145CD56 Q55317014-7C7153B5-BA76-42E1-98BC-752772E4A1A9

P2860

Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.

http://www.wikidata.org/entity/Q33560520

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@ast

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@en

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@nl

type

label

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@ast

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@en

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@nl

prefLabel

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@ast

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@en

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@nl

P1433

Q33560520-6DAB1D6F-2B93-4BEB-B895-D3CC02AE337A

P1476

Q33560520-9336B626-5B2B-4252-820C-A97639E9A72B

P2093

Q33560520-0A41DD97-D766-4823-9AAF-01AF03E1D46D

Q33560520-17AE09E6-E84A-44C0-A743-14DDDD126492

Q33560520-6E40D175-AA95-4542-9A29-5A852FF49A08

Q33560520-8461A481-CE19-4162-9898-D309C7001B5F

Q33560520-958A953F-4B4E-401E-BE72-9430C77F89F9

Q33560520-C541A5CB-683C-4348-A13A-D1B218013B6C

Q33560520-CCDA156F-7A17-4229-8FFA-6E665660D916

Q33560520-D1CA001C-8B51-4216-BDE5-5ED991EBBD6A

Q33560520-EB8FD34F-BF2D-4FD0-A2AF-A091DA2FA82F

P2860

Q33560520-127491F3-DFD7-4E4C-AED3-3EDCC10AF490

Q33560520-15385119-5CD0-4543-A0A0-D447296D4D7D

Q33560520-18952C72-6DE6-491F-9064-8476C5F096ED

Q33560520-2240AB20-D7A8-4E3F-A6E9-8B55EB0AECE9

Q33560520-3F063267-B58E-44D3-B445-5D2F03338A87

Q33560520-50E7F0D2-A618-4BFB-BB6D-73631EFA923E

Q33560520-55155796-0B8D-46B0-B4B4-E759B5DA90BC

Q33560520-5F7FAA6F-F51C-4C3A-B94B-9D48886493C5

Q33560520-85BC25F3-9155-44B0-A324-781EF5CDEED5

Q33560520-8EF4A55C-2B57-467A-BA4E-BD94C943A21B

P304

Q33560520-F73BF084-8B31-479A-B3AE-99B90A828085

P31

Q33560520-DF6681E9-3E07-4F31-BE5B-052F423489F5

P356

Q33560520-990C9F1D-64BF-4EFA-BDF1-A7231187939E

P433

Q33560520-6393ADB3-A99D-4100-A9FE-445BEAE619C2

P478

Q33560520-FF053FFB-77D0-4DEC-BDA4-28FE9DA55199

P577

Q33560520-07E2B1DF-7262-4F04-A466-DE2B1AB277D7

P698

Q33560520-6D518816-8FB9-4A79-A1B8-C84893890205

P921

Q33560520-D040F10E-8915-488F-80C2-3D4ABDC6E627

P932

Q33560520-20E5F98C-B90C-46BE-AFDE-2773D0F90BE6

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Acute hemolysis after high-dos ...... ighly HLA sensitized patients.

@en

P2093

Alice Peng

http://www.w3.org/2001/XMLSchema#string

Ashley A Vo

http://www.w3.org/2001/XMLSchema#string

Ellen Klapper

http://www.w3.org/2001/XMLSchema#string

Eva Barker

http://www.w3.org/2001/XMLSchema#string

Joseph Kahwaji

http://www.w3.org/2001/XMLSchema#string

Rafael Villicana

http://www.w3.org/2001/XMLSchema#string

Robert Chang

http://www.w3.org/2001/XMLSchema#string

Sam Pepkowitz

http://www.w3.org/2001/XMLSchema#string

Stanley C Jordan

http://www.w3.org/2001/XMLSchema#string

P2860

Hemolytic anemia following intravenous gamma globulin administration.

Lack of efficacy of high-dose intravenous immunoglobulin in autoimmune haemolytic anaemia: a clue to its mechanism.

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis.

Risks associated with the use of intravenous immunoglobulin.

Current clinical uses of intravenous immunoglobulin.

Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies

Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences.

Parvovirus-B19-associated complications in renal transplant recipients.

Overview of renal transplantation.

P304

1993-1997

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.04540709

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19833910

http://www.w3.org/2001/XMLSchema#string

P921

P932

2798878

http://www.w3.org/2001/XMLSchema#string